Day One Biopharmaceuticals, (id:7792 DAWN)
13.72 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 9:06:30 AM)
Exchange closed, opens in 1 day
3.08 USD (3.08%)
0.70 USD (0.70%)
-8.35 USD (-8.35%)
-0.58 USD (-0.58%)
12.92 USD (12.92%)
-45.12 USD (-45.12%)
About Day One Biopharmaceuticals,
Market Capitalization 1.38B
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
| Headquarters (address) |
2000 Sierra Point Parkway Brisbane 94005 CA United States |
| Phone | 650 484 0899 |
| Website | https://dayonebio.com |
| Employees | 174 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | DAWN |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 11.30 - 18.07 |
| Market Capitalization | 1.38B |
| P/E trailing | -5.79 |
| P/E forward | -12.25 |
| Price/Sale | 13.57 |
| Price/Book | 2.49 |
| Beta | -1.52 |
| EPS | -0.970 |
| EPS United States (ID:6, base:3402) | 24.22 |